Bevifibatide: First Approval

Bevifibatide (^®; BETAGRIN^®; batifiban) is a cyclic heptapeptide antagonist of glycoprotein IIb/IIIa (GP IIb/IIa; αIIbβ3 integrin receptor) and the αvβ3 integrin receptor. It was developed by Bio-Thera Solutions for the treatment of patients with acute coronary syndrome (ACS) that require percutaneous coronary intervention (PCI). On 25 June 2024, bevifibatide received approval in China for the treatment of patients with a clear diagnosis of ACS who need PCI (including coronary stenting) to reduce the risk of acute occlusion, stent thrombosis, no reflow and slow blood flow. Its first approval is as an add-on to treatment with PCI, antiplatelet and anticoagulant therapies. This article summarizes the milestones in the development of bevifibatide leading to its first approval for reducing the risk of acute occlusion, stent thrombosis, no reflow and slow blood flow in patients with ACS that requires PCI (including coronary stenting).